Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 35%
Hold 29%
Sell 0%
Strong Sell 6%

Bulls say

Arvinas Inc has shown a significant increase in the valuation of its partnered and wholly-owned product candidates, with the total enterprise value rising to $959 million from $627 million, reflecting strong growth prospects. The company's leading candidate, ARV-102, is now valued at $247 million, highlighting its potential in treating LRRK2-related diseases, while ARV-393 and ARV-806 have also seen notable valuation increases. The advancements in their pipeline, particularly in oncology and neurology, combined with early promising data from clinical programs, underpin a positive financial outlook for Arvinas.

Bears say

Arvinas Inc. faces a challenging financial outlook characterized by significant reductions in projected revenue for its product vepdegestrant, which has been decreased from $641.2 million to $296.9 million for 2035, indicative of unfavorable market penetration and partnership economics. The company is also experiencing difficulties in accessing capital, which jeopardizes its ability to maintain critical operations and achieve profitability in a timely manner. Additionally, the upcoming clinical trial data presents uncertainties, as unfavorable results could lead to a halt in the development of its protein degradation agents, further diminishing market potential.

Arvinas Inc (ARVN) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 35% recommend Buy, 29% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 17 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.